Wed, December 31, 2008
Tue, December 30, 2008
Mon, December 29, 2008
Wed, December 24, 2008
Tue, December 23, 2008
Mon, December 22, 2008
Sun, December 21, 2008
Fri, December 19, 2008
Thu, December 18, 2008
Wed, December 17, 2008
Tue, December 16, 2008
Mon, December 15, 2008
Sun, December 14, 2008
Fri, December 12, 2008
Thu, December 11, 2008
Wed, December 10, 2008
Tue, December 9, 2008
Mon, December 8, 2008
Sun, December 7, 2008
Sat, December 6, 2008
Fri, December 5, 2008
Thu, December 4, 2008

Adolor Corporation to Host Conference Call to Provide R&D Update


//health-fitness.news-articles.net/content/2008/ .. -host-conference-call-to-provide-r-d-update.html
Published in Health and Fitness on Wednesday, December 17th 2008 at 12:23 GMT by Market Wire   Print publication without navigation


EXTON, Pa.--([ BUSINESS WIRE ])--Adolor Corporation (Nasdaq:ADLR) today announced that it will hold a conference call at 8:30 a.m. ET on Thursday, December 18, 2008 to provide an R&D program update, including its delta agonist and opioid bowel dysfunction (OBD) programs.

To participate in the audio portion and have the opportunity to pose questions, dial (866) 394-4329 for domestic callers, or (706) 902-1952 for international callers, and enter Conference ID #77986885. Investors also can listen to the call live by logging on to the Company's website at [ www.adolor.com ] and clicking on "Investor Insights," then "Webcast." Please click on the link and follow the prompts for registration and access.

A replay of the call will be available beginning approximately two hours after the event until 11:00 p.m. ET, December 25, 2008. To listen to a replay of the conference call, dial (800) 642-1687 (domestic) or (706) 645-9291 (international) and enter Conference ID #77986855 or listen via Adolor's website. The replay will be available for one week.

About Adolor Corporation

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

Adolor's first approved product in the United States is Entereg® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. Entereg is available for short-term use in hospitals registered under the Entereg Access Support and Education (E.A.S.E.) Program. In collaboration with GlaxoSmithKline, the company launched Entereg in mid-2008. For more information, visit [ www.adolor.com ].


Publication Contributing Sources

Similar Health and Fitness Publications